As of 2026-03-14, the Fair Value of SynAct Pharma AB (SYNACT.ST) is -10.39 SEK. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 18.14 SEK, the upside of SynAct Pharma AB is -157.28%.
With the market price of 18.14 SEK and our fair value calculation, SynAct Pharma AB (SYNACT.ST) is not a good investment. Investing in SYNACT.ST stocks now will result in a potential loss of 157.28%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | 5Y Avg | |
| Net income | -69.30 | -99.20 | -215.81 | -82.40 | -110.83 | -115.51 |
| YoY growth | -161.02% | -43.14% | -117.54% | 61.82% | -34.50% | -58.88% |
| Market Cap (mil) | 967.41 |
| P/E | |
| Forward P/E |
| EPS | -2.08 |
| Avg earnings growth rate | -58.88% |
| TTM earnings | -110.83 |